Delcath Systems/$DCTH
1D1W1MYTD1Y5YMAX
Capital at risk
About Delcath Systems
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
- Ticker
- $DCTH
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 156
- Headquarters
- Queensbury, United States
- Website
- www.delcath.com
Delcath Systems Metrics
BasicAdvanced
$570M
1,118.37
$0.01
0.52
-
Price and volume
Market cap
$570M
Beta
0.52
52-week high
$17.42
52-week low
$8.12
Average daily volume
619K
Financial strength
Current ratio
9.83
Quick ratio
8.447
Long term debt to equity
0.019
Total debt to equity
0.02
Profitability
EBITDA (TTM)
-1.455
Gross margin (TTM)
87.05%
Net profit margin (TTM)
0.56%
Operating margin (TTM)
-1.90%
Effective tax rate (TTM)
58.82%
Revenue per employee (TTM)
$610,000
Management effectiveness
Return on assets (TTM)
-0.89%
Return on equity (TTM)
0.47%
Valuation
Price to earnings (TTM)
1,118.367
Price to revenue (TTM)
6.235
Price to book
4.7
Price to tangible book (TTM)
4.7
Price to free cash flow (TTM)
33.985
Free cash flow yield (TTM)
2.94%
Free cash flow per share (TTM)
0.484
Growth
Revenue change (TTM)
35.85%
Earnings per share change (TTM)
-71.87%
3-year revenue growth (CAGR)
230.76%
10-year revenue growth (CAGR)
49.45%
3-year earnings per share growth (CAGR)
-83.22%
What the Analysts think about Delcath Systems
Analyst ratings (Buy, Hold, Sell) for Delcath Systems stock.
Analyst projections of the future price of Delcath Systems stock.
Bulls say / Bears say
The Q1 2026 results press release reported the publication of full CHOPIN Phase 2 trial results in The Lancet Oncology, demonstrating that adding ipilimumab and nivolumab to percutaneous hepatic perfusion significantly improved progression-free survival in metastatic uveal melanoma (Delcath Q1 Press Release).
The same release highlighted 36% year-over-year growth in HEPZATO KIT volume, driving total revenue to $25.0 million in Q1 2026 and underpinning guidance of at least $100 million for full-year revenue (Delcath Q1 Press Release).
In Q2 2026, Delcath achieved 90% gross margins, up from 86% a year earlier, reflecting improved operational leverage and an enhanced product mix (Delcath Q2 Press Release).
Despite revenue growth, non-GAAP adjusted EBITDA fell 22% year-over-year from $9.8 million in Q2 2025 to $7.6 million in Q2 2026, indicating margin compression as the company scales its clinical programs (Delcath Q2 Press Release).
Net income remained flat at $2.7 million in Q2 2026 versus Q2 2025, suggesting limited progress in translating revenue gains into bottom-line growth (Delcath Q2 Press Release).
The company’s accumulated deficit stood at $527.3 million as of June 30, 2026, underscoring ongoing historical losses despite recent quarterly profitability (Delcath Q2 Press Release).
Data summarised monthly by Lightyear AI. Last updated on 20 Aug 2026.
Delcath Systems Financial Performance
Revenues and expenses
Delcath Systems Earnings Performance
Company profitability
Upcoming events
No upcoming events
Delcath Systems News
AllArticlesVideos
Funds containing Delcath Systems
Fund name | Fund size | $DCTH weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.